Adverum Biotechnologies (ADVM)
(Delayed Data from NSDQ)
$6.70 USD
-0.02 (-0.30%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $6.70 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Fundamental Charts
About PEG Ratio (TTM)
The company's trailing twelve month (TTM) PEG ratio is the P/E ratio divided by its long-term growth rate consensus. This ratio essentially compares the P/E to its growth rate, thus, for many, telling a more complete story than just the P/E ratio alone. Conventional wisdom says that a PEG ratio of 1 or less is considered good (at par or undervalued to its growth rate). A value greater than 1, in general, is not as good (overvalued to its growth rate). For example, a company with a P/E ratio of 25 and a growth rate of 20% would have a PEG ratio of 1.25 (25 / 20 = 1.25). A company with a P/E ratio of 40 and a growth rate of 50% would have a PEG ratio of 0.80 (40 / 50 = 0.80). Traditionally, investors would look at the stock with the lower P/E and deem it a bargain. But when compared to its growth rate, it doesn't have the earnings growth to justify its P/E. In this example, the one with the P/E of 40 is the better bargain because it is selling at a discount to its growth rate. So the PEG ratio tells you what you're paying for each unit of earnings growth.
ADVM 6.70 -0.02(-0.30%)
Will ADVM be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ADVM based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ADVM
Ginkgo (DNA) to Report Q2 Earnings: What's in the Cards?
Is a Beat in the Cards for Incyte (INCY) in Q2 Earnings?
ADVM: What are Zacks experts saying now?
Zacks Private Portfolio Services
What's in Store for Structure Therapeutics (GPCR) in Q2 Earnings?
Geron (GERN) to Report Q2 Earnings: What's in the Cards?
Is a Beat in the Cards for CRISPR (CRSP) in Q2 Earnings?
Other News for ADVM
Adverum Biotechnologies to Participate in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference
Truist Financial Keeps Their Buy Rating on Adverum Biotechnologies (ADVM)
Adverum Biotechnologies Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted for Ixo-vec for the Treatment of Wet AMD
Around $88M Bet On NextDecade? Check Out These 3 Stocks Insiders Are Buying
Adverum Biotechnologies announces FDA RMAT designation for Ixo-vec